PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. - Wikidata - wikimedia - TriplyDB

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

http://www.wikidata.org/entity/Q38219092

about

Improved drug therapy: triangulating phenomics with genomics and metabolomics.Homologues of xenobiotic metabolizing N-acetyltransferases in plant-associated fungi: Novel functions for an old enzyme family.Serum uric acid levels during leprosy reaction episodes.Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients.Pharmacogenetic considerations in the treatment of gout.Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.Uric Acid and Neurocognitive Function in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association.Effect of acetaminophen on sulfamethazine acetylation in male volunteers.

P2860

Q34436487-AC059502-8E21-4F3B-B357-CDAA9D6FF740 Q35973985-6EB5EE57-9B07-4445-952F-E90EC8378DBD Q36691324-F8264DF0-6078-4E2D-B261-D6909F2622AE Q37030180-822462A1-6DF5-42B7-A05C-A698B70586CE Q38422218-A4514354-AC32-422C-8A36-E83472B9C255 Q38600529-687D495C-0B34-44F1-AD12-E0F98072318B Q38848380-2172D3AE-6E2F-46CF-8CB6-260FCA1AB999 Q38970541-55E6ADB0-FF67-4BBC-B65C-4213D819A5CF Q47665232-E95C6A29-0B4A-45BD-9C66-CEFCB0A82125 Q53128563-880135DE-CD55-434C-8D78-4FAD5C5DAF8E Q55013213-4A0CAF42-22DF-4762-8030-B06804977DB6

P2860

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

http://www.wikidata.org/entity/Q38219092

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

@en

type

label

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

@en

prefLabel

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

@en

P1433

Q38219092-047F6A5B-C8A3-4ADC-A765-B53D5E39E899

P1476

Q38219092-2DAB01C7-A7C9-4DB0-86D8-B7D148B792CB

P2093

Q38219092-0B8D639B-2F93-4962-9035-0749F2499009

Q38219092-62ABD0B2-430D-4F8D-AB1B-4CD7AF4B73FB

Q38219092-918069C9-232B-43F4-B2ED-8D37F918375E

P2860

Q38219092-00D619C2-F16D-4B99-9F60-B409374C32A4

Q38219092-017541A0-51A3-4E6D-8866-56152BBB3587

Q38219092-01F73EB2-CAA6-4212-90E4-6322DF66F2D1

Q38219092-038B2382-789F-4F48-A1E1-EA276512E61D

Q38219092-03C517AE-83D2-4447-9A79-8C6C9C92FE41

Q38219092-0827B3C1-D96B-4669-8717-502EBCC824B0

Q38219092-16A07FCB-FB04-4A7E-A963-AB39E3FE79BE

Q38219092-206CF025-52CD-43BD-8D54-E793BC210C37

Q38219092-21844D7E-6321-42E6-96A9-EB780E4507A3

Q38219092-21E02A5F-79E1-43F9-B7F1-172749B479D9

P304

Q38219092-6E9F9582-B325-48BB-981F-FAAACAC88521

P31

Q38219092-7C3292F4-1DF1-4165-892C-DCD4406FA7F4

P356

Q38219092-168AAAC6-270A-4B51-8FFF-BD4214CFD684

P433

Q38219092-3E17EF45-C8E9-4763-B696-2D2C05DF3CF1

P478

Q38219092-1590B50F-20BB-4EE0-B967-D9FEEB819457

P50

Q38219092-58972694-744E-4670-B65D-D39C64D87F41

Q38219092-C53036A9-49E3-43EA-B893-ABBD2AEAAE9D

P577

Q38219092-F5D73F9E-5F29-45D4-BDD3-C4DA3F52EB4B

P698

Q38219092-63481406-F1CA-4D3A-9F55-4605DAA1933E

P932

Q38219092-D8E4CEA3-6F77-4490-8F27-CC789610D95F

P356

FPC.0000000000000058

P1433

Pharmacogenetics and Genomics

P1476

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

@en

P2093

Caroline F Thorn

http://www.w3.org/2001/XMLSchema#string

John T Callaghan

http://www.w3.org/2001/XMLSchema#string

Teri E Klein

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations

Molecular identification of a renal urate anion exchanger that regulates blood urate levels

Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion

Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules

Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13)

Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

Nomenclature for factors of the HLA system, 2010

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Genome-wide association analyses identify 18 new loci associated with serum urate concentrations

P304

464-476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0000000000000058

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24915143

http://www.w3.org/2001/XMLSchema#string

P932

4122637

http://www.w3.org/2001/XMLSchema#string